Skip to content

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06607731
Enrollment
11
Registered
2024-09-23
Start date
2024-06-25
Completion date
2024-12-31
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Angioma

Keywords

percutaneous sclerosis, ethanol gel, aggressive bone angioma

Brief summary

The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.

Interventions

OTHERCollecting data from medical records

Data collected: clinical data (particularly pain), biological data, imaging.

Sponsors

Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne.

Exclusion criteria

* Patients no treated by gelled alcohol sclerotherapy.

Design outcomes

Primary

MeasureTime frameDescription
Number of complications identified in data collectionDay 1Number of complications identified in data collection

Secondary

MeasureTime frameDescription
Number of lesion identified in data collectionDay 1Number of lesion identified in data collection

Countries

France

Contacts

Primary ContactSylvain GRANGE, MD
sylvain.grange@chu-st-étienne.fr(0)477829066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026